Postmarketing surveillance of new drugs: II. Case studies.
D001380:Azauridine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D001437:Bacteriuria / Q000209:etiology; D003276:Contraceptives, Oral / Q000009:adverse effects; D003365:Costs and Cost Analysis; D004311:Double-Blind Method; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007649:Ketamine / Q000009:adverse effects; D007980:Levodopa / Q000009:adverse effects; D012107:Research Design; D014481:United States; D014486:United States Food and Drug Administration; D014635:Valproic Acid / Q000009:adverse effects
D003276:Contraceptives, Oral; D007980:Levodopa; D014635:Valproic Acid; D007649:Ketamine; D001380:Azauridine